Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy ...

Reflecting on past journal entries reminds columnist Kristin Neva that life as an ALS caregiver is always a mix of good and hard times.

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

The ALS Association is urging members of Congress to take action to address issues with instability in leadership at the NIH.

Shionogi plans to acquire global rights to Radicava and Radicava ORS for ALS through a new U.S. business formed by Tanabe ...

With ALS, columnist Dagmar Munn says she must focus her mind and make deliberate choices when decision-making fatigue sets in.

Health Canada has cleared the way for ALS patients in that nation to join the ongoing ALSTARS U.S. trial testing therapy ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Even after 15 years with her husband's ALS, losing caregivers still brings about grief and stress for columnist Kristin Neva.

For columnist Dagmar Munn, using the momentum of "swingtime" is helping her manage ALS-related stress and get through tasks.

ALS patients and their caregivers benefit most from flexible psychological support that combines emotional care, open ...